Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Natera, Inc. reported a significant quarter for Q3 2024, demonstrating positive developments and some challenges inherent in its operations.</li><li>The company achieved a notable revenue increase, reaching $439.8 million, marking a 64% rise compared to the previous year.</li><li>This growth is largely attributed to robust performance across its testing portfolio, particularly within the oncology sector, where the company performed around 137,000 oncology tests, reflecting a substantial 54% year-over-year increase.</li></ul>

Natera, Inc. reported a significant quarter for Q3 2024, demonstrating positive developments and some challenges inherent in its operations.The company achieved a notable revenue increase, reaching $439.8 million, marking a 64% rise compared to the previous year.This growth is largely attributed to robust performance across its testing portfolio, particularly within the oncology sector, where the company performed around 137,000 oncology tests, reflecting a substantial 54% year-over-year increase.

Natera Inc.: These Are The 6 Biggest Factors Impacting Its Performance In 2025 &Beyond! - Major Drivers

<ul><li>Natera, Inc., during its Q1 2024 discussion, presented results that indicate robust financial and operational achievements alongside a renewed forward outlook reflecting the company's strong position in the genomic diagnostics market.</li><li>The company noted a significant increase in its revenue and volume growth across its diversified operational segments, which include oncology, organ health, and women's health.</li><li>Notably, Natera, Inc. achieved a major corporate milestone by reaching cash flow breakeven in Q1, significantly ahead of schedule.</li></ul>

Natera, Inc., during its Q1 2024 discussion, presented results that indicate robust financial and operational achievements alongside a renewed forward outlook reflecting the company's strong position in the genomic diagnostics market.The company noted a significant increase in its revenue and volume growth across its diversified operational segments, which include oncology, organ health, and women's health.Notably, Natera, Inc. achieved a major corporate milestone by reaching cash flow breakeven in Q1, significantly ahead of schedule.

Natera Inc.: Why We Are Neutral Despite These 5 Massive Growth Drivers! - Financial Forecasts

<ul><li>Natera, Inc.'s latest quarterly earnings reveal positive growth prospects and the firm's commitment to maintaining momentum in their healthcare ventures.</li><li>The company saw a rise in revenue, reaching $311 million for Q4, a substantial growth of 43% over the same period in 2022.</li><li>Furthermore, its full-year revenues were reported at $1.08 billion, up by more than 30% compared to the previous year.</li></ul>

Natera, Inc.'s latest quarterly earnings reveal positive growth prospects and the firm's commitment to maintaining momentum in their healthcare ventures.The company saw a rise in revenue, reaching $311 million for Q4, a substantial growth of 43% over the same period in 2022.Furthermore, its full-year revenues were reported at $1.08 billion, up by more than 30% compared to the previous year.

Natera Inc.: Initiation Of Coverage - Can It Successfully Leverage The Invitae Acquisition? - Major Drivers

Fundamental Short Selling Research

Eric Fernandez, CFA

TwoRiversAnalytics

<ul>
<li>Liquidity shorts can be great short candidates.  The key characteristic is that the company may not be viable, economically, given their cash flows and cash requirements. </li>
<li>Liquidity shorts have built-in catalysts, have moderate to higher betas,  and can have strong down moves if a crisis develops.  They can go bankrupt, pushing the stock price near zero.</li>
<li>Today we are flagging Natera, Silk Road Med, Floor &amp; Decor Hldgs</li>
</ul>


Liquidity shorts can be great short candidates.  The key characteristic is that the company may not be viable, economically, given their cash flows and cash requirements. 
Liquidity shorts have built-in catalysts, have moderate to higher betas,  and can have strong down moves if a crisis develops.  They can go bankrupt, pushing the stock price near zero.
Today we are flagging Natera, Silk Road Med, Floor &amp; Decor Hldgs


Weekly Liquidity Risk Short Candidates: Natera, Silk Road Med, Floor & Decor Hldgs

<ul>
<li>Liquidity shorts can be great short candidates.  The key characteristic is that the company may not be viable, economically, given their cash flows and cash requirements. </li>
<li>Liquidity shorts have built-in catalysts, have moderate to higher betas,  and can have strong down moves if a crisis develops.  They can go bankrupt, pushing the stock price near zero.</li>
<li>Today we are flagging Blink Charging., Natera, Axonics, and Enviva.</li>
</ul>


Liquidity shorts can be great short candidates.  The key characteristic is that the company may not be viable, economically, given their cash flows and cash requirements. 
Liquidity shorts have built-in catalysts, have moderate to higher betas,  and can have strong down moves if a crisis develops.  They can go bankrupt, pushing the stock price near zero.
Today we are flagging Blink Charging., Natera, Axonics, and Enviva.


Liquidity Risk Short Candidates: Blink Charging, Natera, Axonics, Enviva

United States

Natera, Inc. operates as a diagnostics company. The Company provides preconception and prenatal genetic testing services. Natera also offers pre-implantation genetic diagnosis, aneuploidy screening, translocation, and single gene testing services.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Natera Inc (NTRA US)

Natera Inc.: These Are The 6 Biggest Factors Impacting Its Performance In 2025 &Beyond! - Major Drivers

Natera, Inc. reported a significant quarter for Q3 2024, demonstrating positive developments and some challenges inherent in its operations. The...

Baptista Research

Natera Inc.: Why We Are Neutral Despite These 5 Massive Growth Drivers! - Financial Forecasts

Natera, Inc., during its Q1 2024 discussion, presented results that indicate robust financial and operational achievements alongside a renewed...

Baptista Research

Natera Inc.: Initiation Of Coverage - Can It Successfully Leverage The Invitae Acquisition? - Major Drivers

Natera, Inc.'s latest quarterly earnings reveal positive growth prospects and the firm's commitment to maintaining momentum in their healthcare...

Baptista Research

Weekly Liquidity Risk Short Candidates: Natera, Silk Road Med, Floor & Decor Hldgs

Liquidity risk short candidates may not be economically viable given cash flows and capital requirements. This week we flag Natera, Silk Road Med,...

Eric Fernandez, CFA

Liquidity Risk Short Candidates: Blink Charging, Natera, Axonics, Enviva

Liquidity risk short candidates may not be economically viable given cash flows and capital requirements. This week we flag Blink Charging,...

Eric Fernandez, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)